XIENCE 28 Global Study
A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 963 participants.
Also called NCT03355742
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 963 participants
- Sponsor
- Registry
-
NCT03355742
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Austria, Belgium, China, Germany, Hong Kong SAR China, Italy, Netherlands, Portugal, Singapore, Spain, Switzerland, Taiwan, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT03355742. Allocation not applicable; no masking; primary purpose treatment. Start 2018-02-09 (actual); primary completion 2019-10-24 (actual). Results posted on 2021-02-08.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- XIENCE 28 Global Study
- Condition
- Bleeding Disorder
- Condition
- Stroke, Ischemic
- Condition
- Stroke Hemorrhagic
- Condition
- Hematological Disease
- Condition
- Thrombocytopenia
- Condition
- Coagulation Disorder
- Condition
- Anemia
- Condition
- Renal Insufficiency
- Condition
- Coronary Artery Disease
- Intervention (Device)
- XIENCE
- Intervention (Drug)
- DAPT
- Lead sponsor
- Abbott Medical Devices
Record details
- Record id
cardio:ct-nct03355742- Content hash
04b348304a4978b9707f92da7ded3f45a0b327df4ab40e4773cb73e0d58fafda